Luttium-177[T½=6.76d;Eβ(max)=0.497MeV;最大组织范围〜2.5mm;208keVγ射线]是用于治疗各种肿瘤和非肿瘤疾病的最重要的治疗放射性同位素之一。本综述记录了过去十年中177Lu-放射性制药的进步,重点是通过直接176Lu生产的177Lu(n,γ)177Lu中通量研究堆中的核反应。描述了通过各种途径生产177Lu的具体细微差别,并讨论了它们的优缺点。Luttium,是镧系元素系列中的最后一个元素。它的化学性质在制备各种显示出明显的体内稳定性的放射性药物中起着至关重要的作用。讨论了用于177Lu标记的传统双功能螯合剂(BFC),并重点介绍了即将出现的螯合剂。提供了在临床前和临床环境中导致各种基于177Lu的放射性药物增长的研究工作。这篇综述还总结了使用有效的177Lu基放射性药物进行临床研究的结果,这些药物是使用研究反应堆中直接中子活化路线产生的中等比活度177Lu制备的。总的来说,该审查充分证明了中等特定活性177Lu在配制各种临床有用的放射性药物方面的实用性,特别是为了在反应堆设施有限的发展中国家数百万癌症患者的利益。
Lutetium-177 [T½ = 6.76 d; Eβ (max) = 0.497 MeV; maximum tissue range ~2.5 mm; 208 keV γ-ray] is one of the most important theranostic radioisotope used for the management of various oncological and non-oncological disorders. The present
review chronicles the advancement in the last decade in 177Lu-radiopharmacy with a focus on 177Lu produced via direct 176Lu (n, γ) 177Lu nuclear reaction in medium flux research reactors. The specific nuances of 177Lu production by various routes are described and their pros and cons are discussed. Lutetium, is the last element in the lanthanide series. Its chemistry plays a vital role in the preparation of a wide variety of radiopharmaceuticals which demonstrate appreciable in vivo stability. Traditional bifunctional chelators (BFCs) that are used for 177Lu-labeling are discussed and the upcoming ones are highlighted. Research efforts that resulted in the growth of various 177Lu-based radiopharmaceuticals in preclinical and clinical settings are provided. This
review also summarizes the results of clinical studies with potent 177Lu-based radiopharmaceuticals that have been prepared using medium specific activity 177Lu produced by direct neutron activation route in research reactors. Overall, the
review amply demonstrates the practicality of the medium specific activity 177Lu towards formulation of various clinically useful radiopharmaceuticals, especially for the benefit of millions of cancer patients in developing countries with limited reactor facilities.